2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow SepNet - Critical Care Trials Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Albumin Replacement Therapy in Septic Shock Albutein® 200 g/L or Plasbumin® 20 - Septic Shock | Phase 3 | Terminated | Jena University Hospital | 440 | 2019-10-21 | 2024-10-28 |
| Hydrocortisone for Prevention of Septic Shock Placebo, Hydrocortisone - Severe Sepsis | Phase 3 | Completed | Charite University, Berlin, Germany | 380 | 2009-01-01 | 2013-09-27 |
| Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial) 10% Hemohes® (10% Hydroxyethyl starch), Sterofundin® (Ringer lactate solution), Actrapid® (Insulin) - Severe Sepsis, Septic Shock | Phase 3 | Completed | SepNet - Critical Care Trials Group | 600 | 2003-04-01 | 2016-02-11 |
Sepsis (3) · Shock, Septic (2) · Shock (1)
Albumins (1) · Hydrocortisone (1) · Hydroxyethyl Starch Derivatives (1) · Insulin (1) · sterofundin (1)
Germany (3)
Konrad Reinhart, MD (2) · Didier Keh, MD (1) · Frank M Brunkhorst, MD (1) · Markus Loeffler, MD (1) · Thomas Deufel, MD (1) · Yasser Sakr, MD, PhD (1)
PMID 18184958, PMID 27695824, PMID 33287911, PMID 36345013, PMID 41712212
2018 (1)